Mallinckrodt dives as sales of main drug Acthar disappoint

(Reuters) - Shares of Mallinckrodt Plc plunged more than 30 percent to an all-time low on Tuesday after the drugmaker reported disappointing quarterly revenue and warned of slower sales of Acthar, its biggest source of revenue.